Corteria Pharmaceuticals

Corteria Pharmaceuticals is a privately held, clinical-stage biotech based in Paris, developing novel small molecule and biologic therapies for cardiovascular and metabolic disorders. The company's lead programs are two first-in-class CRF2 receptor agonists targeting worsening heart failure and obesity/right heart failure, with one asset entering Phase 2 and another in Phase 1. Leveraging deep cardiovascular R&D expertise from its leadership, Corteria aims to address significant unmet needs in heart failure decompensation through a precision medicine approach.

Biology-driven patient stratification and target selection based on human evidence, focusing on neuro-endocrine pathways in heart failure decompensation. Utilizes both small molecule (CRF2 agonists) and biologic (vasopressin antibody) modalities.

Competes in the crowded heart failure space against standard diuretics, SGLT2 inhibitors, ARNIs, and other novel mechanisms in development. Its CRF2 agonists are first-in-class, offering potential differentiation, but face competition from other decongestive strategies and disease-modifying agents.